Please provide your email address to receive an email when new articles are posted on . Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had ...
Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to ...
In 2015, when the first cholesterol-lowering drugs targeting a protein called PCSK9 were about to hit the market, anticipation in the cardiovascular community ran high. Elevated levels of low-density ...
The role of PCSK9 inhibitors as treatment for dyslipidemia now that statin therapies are available. Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to ...
Amgen’s (NASDAQ:AMGN) agreement with RNA interference specialist Arrowhead Pharmaceuticals will see it develop two RNAi therapies for cardiovascular disease, putting it on track for a showdown with ...
Merck & Co. has completed a hat trick of phase 3 victories for its oral PCSK9 inhibitor. Navigating into the broader hyperlipidemia population, the drugmaker stayed out of the shoals and charted a ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results